https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-752013-06-24 00:00:002013-06-24 00:00:00Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)2013-06-03 00:00:002013-06-03 00:00:00Role of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e13029)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e13029)2013-05-31 00:00:002013-05-31 00:00:00Outcome of an advanced anaplastic astrocytoma patient treated with Newcastle disease viral (NDV) oncolytic therapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-542013-03-18 00:00:002013-03-18 00:00:00The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-8002013-01-23 00:00:002013-01-23 00:00:00Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Transl Res 2013 Apr;161(4):355-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Transl Res 2013 Apr;161(4):355-642013-01-10 00:00:002019-02-15 09:22:40Oncolytic virus therapy for cancer: the first wave of translational clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-10 / JOP 2012 Sep;13(5):502-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-10 / JOP 2012 Sep;13(5):502-132012-09-10 00:00:002012-09-10 00:00:00Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-352012-08-19 00:00:002019-02-15 09:22:38The use of oncolytic viruses to overcome lung cancer drug resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
